Pfizer and biontech receive u.s. fda emergency use authorization for omicron ba.4/ba.5-adapted bivalent covid-19 vaccine in children under 5 years

New york & mainz, germany--( business wire )--pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced the u.s. food and drug administration (fda) granted emergency use authorization (eua) of their omicron ba.4/ba.5-adapted bivalent covid-19 vaccine as the third 3-Μg dose in the three-dose primary series for children 6 months through 4 years of age. children in this age group can receive a primary series consisting of two 3-Μg doses of the original pfizer-biontech covid-19 vaccine followed by a third 3-Μg dose of the bivalent vaccine to complete the primary series. vaccine doses can be delivered immediately upon receipt of a recommendation from the u.s. centers for disease control and prevention ("cdc").
BNTX Ratings Summary
BNTX Quant Ranking